We have long been writing about a series of problems with K-V Pharmaceutical Company. In December, K-V Pharmaceutical said that the U.S. Food and Drug Administration (FDA) accepted its work plan to address the issues. Now, KV Pharmaceutical said it will be closing down its ETHEX generic drug unit, wrote The Associated Press (AP). The drug maker will also plead guilty to criminal charges that allege ETHEX neglected to appropriately advise regulators about significant manufacturing problems that posed dangers to consumers, wrote the AP.
Last March, we wrote that the U.S. Food and Drug Administration (FDA) announced that a Consent Decree of permanent injunction was filed enjoining KV Pharmaceutical Company, its subsidiaries ETHEX Corporation and Ther-Rx Corporation, and its principal officers, from making and distributing adulterated and unapproved drugs. That move followed an extensive series of incidents regarding KV Pharmaceuticals and its subsidiaries. More KV Pleads Guilty, Agrees to Close ETHEX Generic Drug Plant


